From 39b89a44b70e381b8e9f02b1fb32dc2790eb497a Mon Sep 17 00:00:00 2001 From: will king Date: Thu, 5 Sep 2024 23:47:42 -0700 Subject: [PATCH] minor tweak to intro --- Latex/Paper/sections/01_introduction.tex | 21 +++++++++------------ 1 file changed, 9 insertions(+), 12 deletions(-) diff --git a/Latex/Paper/sections/01_introduction.tex b/Latex/Paper/sections/01_introduction.tex index 4d6e22e..4b8fda1 100644 --- a/Latex/Paper/sections/01_introduction.tex +++ b/Latex/Paper/sections/01_introduction.tex @@ -47,19 +47,16 @@ Thus being able to isolate the effect of operational challenges from strategic decisions allows us to predict the intended or unintended effects of a given policy on clinical trials. -In this work, I propose a model of clinical trial progression that allows -me to separate the effects of competing drugs (a strategic concern) -and struggles recruiting (an operational concern). -I also use a novel dataset extracted from +In this work, I focus on separating the effects of enrollment and +competing drugs on clinical trial completion, specifically Phase III trials. +To do this, I create a + dataset extracted from \url{ClinicalTrials.gov} that tracks individual clinical trials as they progress towards completion -to estimate the effects of competing drugs and difficulty recruiting. -Similar to -\cite{hwang_failure_2016} -I focus on clinical trials in Phase III trials for drug compounds. -Not all of these trials will be to test novel compounds, as many -are trials to use previously approved compounds for new indications -or in combination with other treatments. - +as well as a novel causal model of individual clinical trial progression. +Unlike previous research which is focused on the drug development pipeline, I +restrict my investigation to modelling individual clinical trials. +The goal of this restriction is to provide a way to predict the impact +of changes that affect enrollment independent of other confounding effects. \end{document}